Palatin Technologies Inc. filed SEC Form 8-K: Shareholder Director Nominations

$PTN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PTN alert in real time by email
ptn_8k.htm

   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

 

Date of Report (Date of earliest event reported): September 5, 2024

 

Palatin Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-15543

 

95-4078884

(State or other jurisdiction

 

(Commission

 

(IRS employer

of incorporation)

 

File Number)

 

identification number)

 

4B Cedar Brook Drive, Cranbury, NJ

 

08512

(Address of principal executive offices)

 

(Zip Code)

 

Registrant's telephone number, including area code: (609) 495-2200

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol

 

Name of Each Exchange

on Which Registered

Common Stock, par value $.01 per share

 

PTN

 

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.08 Shareholder Director Nominations.

 

Palatin Technologies, Inc. (the “Company”) has established December 12, 2024 as the date of the Company’s annual meeting of stockholders for the fiscal year ended June 30, 2024 (the “Annual Meeting”), and October 28, 2024 as the record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting. The time, place, and detailed information regarding the proposals to be presented at the Annual Meeting will be set forth in a Definitive Proxy Statement on Schedule 14A to be filed with the U.S. Securities and Exchange Commission.

 

Because the date of the Annual Meeting will be more than 30 days from the anniversary of the Company’s annual meeting of stockholders for the fiscal year ended June 30, 2023 held on June 27, 2024, the deadline for submission of proposals by stockholders for inclusion in the Company’s proxy materials for the Annual Meeting, in accordance with Rule 14a-8 under the Exchange Act of 1934, as amended (the “Exchange Act”), will be October 21, 2024, which the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials. Any such proposal must also meet the requirements set forth in the rules and regulations of the Exchange Act in order to be eligible for inclusion in the proxy materials for the Annual Meeting.

 

In addition, in accordance with the Company’s Amended and Restated Bylaws, any stockholder who intends to nominate a person for election as a director or submit a proposal for inclusion at the Company’s Annual Meeting must provide notice on or before the close of business on September 13, 2024. Such notice must comply with the specific requirements set forth in the Company’s Amended and Restated Bylaws in order to be considered at the Annual Meeting. Any such proposal shall be marked for the attention of the Secretary and mailed to our executive offices, 4B Cedar Brook Drive, Cranbury, NJ 08512.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PALATIN TECHNOLOGIES, INC.

 

 

 

 

 

Date: September 6, 2024

By:

/s/ Stephen T. Wills

 

 

 

Stephen T. Wills, CPA, MST

 

 

 

Executive Vice President, Chief Financial Officer and Chief Operating Officer

 

 

 

3

 

Get the next $PTN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PTN

DatePrice TargetRatingAnalyst
11/24/2021$2.00 → $5.00Buy
HC Wainwright & Co.
More analyst ratings

$PTN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

    Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

    CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

    CRANBURY, N.J., Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the "Registered Direct Offering") at a purchase price of $1.00 per share.

    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PTN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PTN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PTN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PTN
SEC Filings

See more

$PTN
Financials

Live finance-specific insights

See more
  • Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

    Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

    CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

    Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a

    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PTN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more